The trial follows a prospective randomized controlled design comparing the twice daily intake of green tea extract containing 150 mg EGCG supplement to a placebo. Patients will be randomized after a verum run-in period of one month to receive either green tea extract containing 150 mg EGCG two times daily or placebo over the course of three years.